MY142756A - Crystalline composition containing escitalopram. - Google Patents
Crystalline composition containing escitalopram.Info
- Publication number
- MY142756A MY142756A MYPI20050870A MYPI20050870A MY142756A MY 142756 A MY142756 A MY 142756A MY PI20050870 A MYPI20050870 A MY PI20050870A MY PI20050870 A MYPI20050870 A MY PI20050870A MY 142756 A MY142756 A MY 142756A
- Authority
- MY
- Malaysia
- Prior art keywords
- escitalopram
- crystalline particles
- composition containing
- escitalopram oxalate
- crystalline composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Abstract
THE PRESENT INVENTION DISCLOSES CRYSTALLINE PARTICLES OF ESCITALOPRAM OXALATE WHICH EITHER HAVE A BROAD PARTICLE SIZE DISTRIBUTION OR COMPRISE AT LEAST 0.01 % (W/W) OF Z-4-(4-DIMETHYLAMINO-1 -(4-FLUOROPHENYL)-BUT-1 -ENYL)-3-HYDROXYMETHYL- BENZONITRILE, SAID PARTICLES BEING SUITABLE FOR USE IN DIRECT COMPRESSION. FURTHERMORE, THE INVENTION DISCLOSES A NOVEL PHARMACEUTICAL UNIT DOSAGE FORM CONTAINING SUCH CRYSTALLINE PARTICLES OF ESCITALOPRAM OXALATE AS WELL AS METHODS FOR MANUFACTURE OF SUCH CRYSTALLINE PARTICLES OF ESCITALOPRAM OXALATE FINALLY, THE INVENTION PROVIDES A METHOD FOR REDUCTION OF THE AMOUNT OF HYDROXYL CONTAINING IMPURITIES IN A SOLUTION OF CITALOPRAM OR ESCITALOPRAM.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200400382 | 2004-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY142756A true MY142756A (en) | 2010-12-31 |
Family
ID=36607154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI20050870A MY142756A (en) | 2004-03-05 | 2005-03-03 | Crystalline composition containing escitalopram. |
Country Status (9)
Country | Link |
---|---|
KR (1) | KR20060126587A (en) |
CN (3) | CN101492435A (en) |
AR (1) | AR047749A1 (en) |
IL (1) | IL177504A0 (en) |
MY (1) | MY142756A (en) |
PE (1) | PE20051162A1 (en) |
SG (1) | SG159504A1 (en) |
TW (1) | TW200605916A (en) |
ZA (1) | ZA200607382B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114763343A (en) * | 2021-01-14 | 2022-07-19 | 浙江华海药业股份有限公司 | Method for purifying citalopram or S-citalopram |
CN113663356B (en) * | 2021-08-23 | 2022-09-23 | 广西埃索凯新材料科技有限公司 | Crystallization impurity removal monitoring system applied to manganese sulfate production |
-
2005
- 2005-02-17 TW TW094104639A patent/TW200605916A/en unknown
- 2005-02-21 KR KR1020067017907A patent/KR20060126587A/en not_active Application Discontinuation
- 2005-02-21 SG SG201000567-6A patent/SG159504A1/en unknown
- 2005-02-21 CN CNA2009100028557A patent/CN101492435A/en active Pending
- 2005-02-21 ZA ZA200607382A patent/ZA200607382B/en unknown
- 2005-02-21 CN CNA2005800069400A patent/CN1925844A/en active Pending
- 2005-02-21 CN CNA2009100028561A patent/CN101492436A/en active Pending
- 2005-02-24 AR ARP050100683A patent/AR047749A1/en not_active Application Discontinuation
- 2005-03-02 PE PE2005000241A patent/PE20051162A1/en not_active Application Discontinuation
- 2005-03-03 MY MYPI20050870A patent/MY142756A/en unknown
-
2006
- 2006-08-15 IL IL177504A patent/IL177504A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW200605916A (en) | 2006-02-16 |
CN1925844A (en) | 2007-03-07 |
ZA200607382B (en) | 2008-05-28 |
CN101492435A (en) | 2009-07-29 |
IL177504A0 (en) | 2006-12-10 |
AR047749A1 (en) | 2006-02-15 |
KR20060126587A (en) | 2006-12-07 |
CN101492436A (en) | 2009-07-29 |
SG159504A1 (en) | 2010-03-30 |
PE20051162A1 (en) | 2006-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05010682A (en) | Novel compounds. | |
BR0206164A (en) | Escitalopram oxalate crystalline particles, method for the production of escitalopram oxalate crystalline particles, and solid unit dosage form | |
MY142029A (en) | Phenoxyacetic acid derivatives | |
TW200745003A (en) | Novel compounds | |
WO2004014322A3 (en) | Immunomodulatory compositions, methods of making, and methods of use thereof | |
UA100228C2 (en) | Pharmaceutical composition containing a tetrahydrofolic acid | |
GEP20074030B (en) | Controlled synthesis of ziprasidone and compositions thereof | |
MX2009005455A (en) | (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs. | |
SE0301009D0 (en) | Novel compounds | |
SI1695709T1 (en) | Crystalline form gamma-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it | |
WO2010131922A3 (en) | Amide compound, preparation method thereof and pharmaceutical composition comprising same | |
WO2011065800A3 (en) | Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same | |
MXPA04003858A (en) | Mch antagonists for the treatment of obesity. | |
IL180144A0 (en) | Compositions comprising strontium and vitamin d and uses thereof | |
DE60110054D1 (en) | Cardioprotektive phosphonate | |
UA103179C2 (en) | Pharmaceutical composition comprising ezetimibe | |
TW200510367A (en) | Novel lapachone compounds, their preparation, and the use thereof | |
WO2008102321A3 (en) | Oral polyphosphate compositions | |
UA95088C2 (en) | Composition comprising at least one anticancer drug and at least one polymer and reducing chemotherapy-induced alopecia, process for the preparation thereof | |
IL160171A0 (en) | Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
TW200718698A (en) | Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof | |
MY137846A (en) | Processes for the preparation of oral dosage formulations of modafinil | |
HK1126194A1 (en) | Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | |
EA200601641A1 (en) | CRYSTAL COMPOSITION CONTAINING ESCYTAL PREMAX OXALATE | |
MY142756A (en) | Crystalline composition containing escitalopram. |